Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568420 | 0.96 | HSP90AB1 (0.47) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL2566599 | 0.95 | KCNH2 (0.43) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL2562416 | 0.90 | HSP90AB1 (0.46) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL3955703 | 0.88 | HSP90AB1 (0.45) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL13798710 | 0.87 | HSP90AB1 (0.65) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL4064357 | 0.83 | HSP90AB1 (0.48) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL2569133 | 0.82 | HSP90AB1 (0.46) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL2568885 | 0.82 | HSP90AB1 (0.48) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL3955735 | 0.82 | HSP90AA1 (0.62) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL13798712 | 0.82 | KCNH2 (0.62) | HSP90AB1KCNH2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | HSP90AB1 2/4885KCNH2 2202/4885HSP90AA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.